Stonebridge Financial Planning Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Stonebridge Financial Planning Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,588	Closed	-$229K	–	367
2021 Q4	$229K	Sell	2,588 -750	-22%	-$90.5K	0.12%	113
2021 Q3	$448K	Sell	3,338 -695	-17%	-$89.5K	0.22%	79
2021 Q2	$532K	Sell	4,033 -270	-6%	-$35.5K	0.28%	72
2021 Q1	$547K	Hold	4,303	–	–	0.32%	63
2020 Q4	$606K	Buy	4,303 +1,225	+40%	+$157K	0.38%	52
2020 Q3	$371K	Buy	3,078 +155	+5%	+$17.4K	0.27%	66
2020 Q2	$330K	Buy	2,923 +2,823	+2,823%	+$278K	0.28%	64
2020 Q1	$8K	Hold	100	–	–	0.01%	331
2019 Q4	$10K	Buy	+100	New	+$8.65K	0.01%	294

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Stonebridge Financial Planning Group's XBI Position: Q1 2022 in Review

Stonebridge Financial Planning Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 2,588 shares — an estimated $229K sold.

Stonebridge Financial Planning Group first reported a position in XBI in Q4 2019 and held it in 9 quarters. The position peaked at $606K in Q4 2020. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Stonebridge Financial Planning Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Stonebridge Financial Planning Group sold 2,588 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $229K.
Stonebridge Financial Planning Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and held it in 9 quarters.
Stonebridge Financial Planning Group's State Street SPDR S&P Biotech ETF position peaked at $606K in Q4 2020.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Stonebridge Financial Planning Group's 13F filing for Q1 2022, filed 10 May 2022.